SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Clinical Development

News in brief

Icon supporting trials to bring TCM to the US

22-Nov-2011

Tasly Pharmaceuticals is working with Icon to have its traditional Chinese medicine (TCM) approved by the US FDA.

China-based Tasly is outsourcing one of its Phase III clinical trials to Icon and using the contract research organisation (CRO) for other tasks. Icon is providing IVRS (interactive voice response systems), data management and central laboratory services to both Dantonic Phase III trials.

 

We look forward to working with Tasly and to helping them in their efforts to become the first provider of [a US Food and Drug Administration] approved traditional Chinese medicine”, Malcolm Burgess, executive vice president, Icon clinical research, said.

Key Industry Events

 

Access all events listing

Our events, Events from partners...

On demand Supplier Webinars

A brief history of bioavailability
William Reed Business Media
Bioavailability market dynamics
William Reed Business Media
All supplier webinars